Biotech firm appoints non-executive director

DRUG development company Redx Pharma has announced the appointment of David Lawrence as a non-executive director as it prepares to move its headquarters from Liverpool to Alderley Park in Cheshire.

Lawrence succeeds Derek Lindsay, who is stepping down from the board of the AIM-listed company, with both changes taking immediate effect. Lindsay will remain with the company as chief operating officer.

Lawrence, aged 53, has more than 25 years’ experience in the biotech and pharmaceutical industries.

He has a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs.

He is currently a non-executive director at Synpromics, a synthetic biology company that he co-founded.

Additionally, he acts as an adviser in the technology sector. In 2014-2015 he was chief executive of Sentintext Therapeutics, a biotech focused on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices.

Between 2010 and 2014, he was Chairman of Ambicare Health, where he oversaw the company’s progression from R&D into revenue generation. Before that, as CEO of Tayside Flow Technologies Ltd (“Tayside”), he led Tayside’s strategic and commercial transformation into a revenue generating company.

Lawrence also worked at a number of major pharmaceutical companies, including Chiron Vaccines, now part of Novartis, Acambis plc, now part of Sanofi, where he was CFO, and he spent the first 13 years of his career at GlaxoSmithKline, latterly as Vice President of R&D Financial Management.

Redx chief executive Neil Murray said: “We are confident David’ss extensive commercial and financial experience in the biotech and pharmaceutical industries will benefit Redx.

“The board would also like to place on record its thanks to Derek Lindsay, who as co-founder has made an enormous contribution to the Company and to the Board. We look forward to continuing to work with Derek in his role as COO.”

Close